12 results on '"Olivia Minelli"'
Search Results
2. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia
- Author
-
Alessandra Carotti, Brunangelo Falini, Massimo F. Martelli, Sara Piccinelli, C. Zucchetti, Loredana Ruggeri, Adelmo Terenzi, Simonetta Saldi, Antonio Pierini, Mauro Di Ianni, Sara Tricarico, Cynthia Aristei, Roberta Iacucci Ostini, Maria Paola Martelli, Olivia Minelli, Mara Merluzzi, Samanta Bonato, Franca Falzetti, Cristina Mecucci, Gianluca Ingrosso, Tiziana Zei, Andrea Velardi, Antonella Mancusi, Sara Ciardelli, Rita Tognellini, and Roberto Limongello
- Subjects
Oncology ,medicine.medical_specialty ,Transplantation Conditioning ,Cyclophosphamide ,medicine.medical_treatment ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,Survival rate ,Aged ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Total body irradiation ,medicine.disease ,Fludarabine ,Leukemia, Myeloid, Acute ,Leukemia ,Graft-versus-host disease ,business ,Whole-Body Irradiation ,medicine.drug - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment in eradicating high-risk acute myeloid leukemia (AML). Here, we present data from a novel HLA-haploidentical HSCT protocol that addressed the 2 remaining major unmet medical needs: leukemia relapse and chronic graft-versus-host disease (cGVHD). Fifty AML patients were enrolled in the study. The conditioning regimen included total body irradiation for patients up to age 50 years and total marrow/lymphoid irradiation for patients age 51 to 65 years. Irradiation was followed by thiotepa, fludarabine, and cyclophosphamide. Patients received an infusion of 2 × 106/kg donor regulatory T cells on day −4 followed by 1 × 106/kg donor conventional T cells on day −1 and a mean of 10.7 × 106 ± 3.4 × 106/kgpurified CD34+ hematopoietic progenitor cells on day 0. No pharmacological GVHD prophylaxis was administered posttransplantation. Patients achieved full donor–type engraftment. Fifteen patients developed grade ≥2 acute GVHD (aGVHD). Twelve of the 15 patients with aGVHD were alive and no longer receiving immunosuppressive therapy. Moderate/severe cGVHD occurred in only 1 patient. Nonrelapse mortality occurred in 10 patients. Only 2 patients relapsed. Consequently, at a median follow-up of 29 months, the probability of moderate/severe cGVHD/relapse-free survival was 75% (95% confidence interval, 71%-78%). A novel HLA-haploidentical HSCT strategy that combines an age-adapted myeloablative conditioning regimen with regulatory and conventional T-cell adoptive immunotherapy resulted in an unprecedented cGVHD/relapse-free survival rate in 50 AML patients with a median age of 53 years. This trial was registered with the Umbria Region Institutional Review Board Public Registry as identification code 02/14 and public registry #2384/14 and at www.clinicaltrials.gov as #{"type":"clinical-trial","attrs":{"text":"NCT03977103","term_id":"NCT03977103"}}NCT03977103.
- Published
- 2021
3. Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests
- Author
-
Alfonso Iorio, Davide Matino, Anthony K.C. Chan, Stefano Lancellotti, Shen Chu Xie, Monica Sacco, Olivia Minelli, and Raimondo De Cristofaro
- Subjects
Prothrombin time ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Immunology ,Antithrombin ,Cell Biology ,Hematology ,Fibrinogen ,Biochemistry ,Gastroenterology ,ADAMTS13 ,Hemostasis ,Internal medicine ,Medicine ,Plasmapheresis ,business ,medicine.drug ,Blood coagulation test ,Partial thromboplastin time - Abstract
Background : Double filtration plasmapheresis (DFPP) is a form of therapeutic plasma exchange (TPE) that removes high-molecular-weight (HMW) pathological mediators from the plasma with two filters: a plasma separator and a plasma fractionator. Relative to simple TPE, the semi-selectiveness of DFPP reduces protein loss and the need for substitution fluid. However, depending on the choice of plasma fractionator, DFPP may negatively impact hemostatic components such as HMW coagulation factors. Aim: To determine the impact of DFPP on various hemostatic parameters (i.e. FVIII activity, fibrinogen level, vWF level and activity, ADAMTS13 level and activity, protein C (PC) activity, protein S (PS) activity, antithrombin (AT) activity, prothrombin time (PT), and activated partial thromboplastin time (aPTT)). Methods: Fourteen patients undergoing weekly, bimonthly, or monthly DFPP sessions for hematologic conditions (n=11) or nervous system disorders (n=3) were recruited. Hemostatic parameters were measured immediately before and after 27 DFPP sessions (1-4 sessions/patient). The treatment volume was standardized at one plasma volume, and anticoagulation was performed with ACD-A citrate dextrose solution. EC-30W and EC-50W were used as the plasma fractionators in 4 and 23 sessions, respectively. In addition to primary data collection, we systematically searched PubMed, MEDLINE, and EMBASE for studies that investigated the impact of DFPP on hemostasis. No restriction was placed on filter choice. Results: In our cohort of 14 patients, all hemostatic changes were statistically significant. After a routine DFPP session, the level and/or activity of HMW proteins (>100kDa: FVIII, fibrinogen, vWF, ADAMTS13) were decreased more than those of low-molecular-weight (LMW) proteins ( Our systematic review included 26 cohort studies, 6 case reports, and 1 randomized controlled trial. Increases in INR and aPTT following DFPP were considerably higher in previous studies, which may relate to the commonality of heparin-induced anticoagulation. The present study is the first comprehensive investigation of the impact of DFPP on hemostatic parameters with such a large sample size. It is also the first study of its nature to measure ADAMTS13-related parameters. Conclusions: Routine DFPP resulted in significant reduction across all investigated hemostatic proteins and significant prolongation of clotting tests. The activities of HMW coagulation-related proteins were decreased more than those of LMW anticoagulation-related proteins. This finding suggests that DFPP may increase overall bleeding risk, a consideration for patient safety that may be of importance in continuous DFPP treatment. Additional high quality evidence is needed to elucidate the effect of DFPP on the hemostatic system. Disclosures Matino: Sanofi: Honoraria; Sobi: Honoraria, Research Funding; Roche: Research Funding; Bayer: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Bioviiix: Honoraria.
- Published
- 2019
4. How Adoptive Immunotherapy with Conventional T and Regulatory T Cells Exerts a Gvl Effect without GvHD, after Haploidentical Hematopoietic Transplantation
- Author
-
Adelmo Terenzi, Elena Urbani, Valentina Lancellotta, Maurizio Caniglia, Massimo F. Martelli, Mara Merluzzi, Mauro Di Ianni, Roberta Iacucci Ostini, Antonio Pierini, Amico Lucia, Sara Ciardelli, Rita Tognellini, Simonetta Saldi, Andrea Velardi, Sara Piccinelli, Olivia Minelli, Brunangelo Falini, Maria Speranza Massei, Mauro Marchesi, Franca Falzetti, Sara Tricarico, Loredana Ruggeri, Tiziana Zei, Alessandra Carotti, and Cynthia Aristei
- Subjects
Cyclophosphamide ,business.industry ,Immunology ,Cell Biology ,Hematology ,Human leukocyte antigen ,medicine.disease ,Biochemistry ,Fludarabine ,Transplantation ,03 medical and health sciences ,Haematopoiesis ,Leukemia ,0302 clinical medicine ,Graft-versus-host disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,Bone marrow ,business ,030215 immunology ,medicine.drug - Abstract
Post-transplant relapse is still a major cause of treatment failure in high-risk acute leukemia (AL) patients. Attempts to manipulate donor T cell alloreactivity to spare normal tissues while killing leukemic cells have been largely unsuccessful. In the search for strategies to separate the GvL effect from GVHD, we investigated the role of a thymic-derived CD4+CD25+ FoxP3+ regulatory T-cell subpopulation (Tregs) that physiologically helps maintain immunological self-tolerance and immune homeostasis. Evidence from murine bone marrow (BM) transplantation across major histocompatibility barriers showed co-infusion of conventional T lymphocytes (Tcons) with Tregs suppressed lethal GVHD without impairing Tcon activity against malignant diseases. In 69 high-risk AL patients who had received an HLA haploidentical T cell-depleted hematopoietic transplant and no post-transplant immunosuppressive GvHD prophylaxis, adoptive immunotherapy with donor Tregs (2 × 106/kg) and Tcons (1 × 106/kg) protected patients from GvHD (Di Ianni et al., Blood 2011) and largely prevented post-transplant leukemia relapse. In fact, only 5% of patients relapsed (Martelli et al., Blood 2014). However, also because such patients had advanced stage disease, TRM was still in the range of that of T cell-depleted haplo transplants, (i.e. 40%, Aversa et al., JCO 2005). A current cohort of AL patients was conditioned with total body irradiation (TBI) (8Gy as single dose TBI or 13.5 Gy as fractionated TBI), cyclophosphamide (30mg/kg), thiotepa (8mg/kg) and fludarabine (200mg/m2). To date, 24 high-risk AL patients (7 ALL, 17 AML) have been enrolled. Twenty-two of the 24 patients engrafted, one AML patient relapsed, 4/22 developed aGvHD (4/4 are alive) and one developed cGvHD, TRM was exceptionally low (Fig. 1). At a median follow up of 2 years, 19 patients are alive. Consequently, probabilities of leukemia-free and leukemia/cGVHD-free survivals are good (Fig. 1). Hypotheses have been put forward to explain the ability of Tregs to prevent of GvHD while preserving the GvL effect mediated by Tcons. However, the mechanism is still unknown. In humans, naïve CD45RA+ Tregs express CXCR4 BM homing receptor and preferentially localize to the BM while memory CD45RO+ Tregs display lower CXCR4 expression and home to the periphery (Booth et al., J Immunol. 2010). Since Tregs that are recovered from peripheral blood and are used for adoptive immunotherapy are CD45RO+ and largely CxCR4 negative, we hypothesized that GvL without GvHD might be due to unopposed Tcon alloreactivity in the BM combined with regulated T cell alloreactivity at the periphery. In order to verify such hypothesis, we infused NSG mice with human leukemia and human Tregs and Tcons. Mice that received leukemia and haploidentical Tcons (without Tregs) cleared leukemia but died of GvHD. T cells harvested from their BM, spleen and liver were predominantly CD8+ and displayed alloreactivity against leukemia. Mice that received leukemia and Tcons plus Tregs were rescued from leukemia and survived without GvHD. T cells harvested from spleen and liver were composed of CD8+ T cells (40%) and CD4+T cells (60%). Purified CD4+ T cells had retained their regulatory function as they inhibited mixed lymphocyte reaction. Purified CD8+ T cells displayed no alloreactivity against leukemia. In contrast, T cells harvested from BM were still predominantly CD8+ and still displayed alloreactivity against leukemia suggesting Tcons had retained their alloantigen recognition. Finally, in mice treated with Tregs alone, T cells were recovered only in the spleen and liver, they displayed a CD4+ phenotype and inhibited mixed lymphocyte reaction. No T cells were found in the BM. In contrast, when we infused human purified CD45RA+ naïve Tregs (that display the CXCR4 BM homing receptor), mice died of leukemia progression despite the co-infusion of large doses of Tcons. In the BM we isolated CD8+ T cells that displayed no ability to kill leukemia and CD4+ T cells that displayed regulatory function. Thus, naïve Tregs homed to the BM and blocked the GvL effect of T cons. When CXCR4 was blocked with an anti-CXCR4 antibody, naïve Tregs could not home to the BM and T cons killed leukemia. In conclusion, Treg-Tcon adoptive immunotherapy confines the graft-versus-host alloreaction to the hematopoietic system and, consequently, allows a GvL effect without GvHD. Figure. Figure. Disclosures No relevant conflicts of interest to declare.
- Published
- 2018
5. Treg/Tcon Immunotherapy and High Dose Marrow Irradiation Ensure Full Control of Leukemia Relapse in Haploidentical Transplantation
- Author
-
Olivia Minelli, Sara Piccinelli, Antonio Pierini, Adelmo Terenzi, Loredana Ruggeri, Cynthia Aristei, Andrea Velardi, Massimo F. Martelli, Simonetta Saldi, Alessandra Carotti, Valentina Lancellotta, and Franca Falzetti
- Subjects
Oncology ,Transplantation ,medicine.medical_specialty ,Adoptive cell transfer ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,Hematology ,ThioTEPA ,Hematopoietic stem cell transplantation ,Total body irradiation ,medicine.disease ,Fludarabine ,Leukemia ,surgical procedures, operative ,Internal medicine ,High Risk Acute Leukemia ,medicine ,business ,medicine.drug - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy for patients with high risk of relapse. In spite of that, no matter the donor source or conditioning regimen used, leukemia relapse is still the leading cause of HSCT failure. In HLA-haploidentical HSCT, we recently applied a clinical protocol consisting of total body irradiation (TBI)-based conditioning regimen and a peripheral blood CD34+ cell graft combined with the adoptive transfer of naturally occurring regulatory T cells (Tregs) and conventional T cells (Tcons). No post-transplant pharmacologic GvHD prophylaxis was given. Such protocol was associated with low GvHD and relapse rate (Martelli et al., Blood 2014). To further reduce leukemia relapse in Treg/Tcon-based haploidentical HSCT (Treg/Tcon haplo-HSCT) we used high dose hyper-fractionated TBI (HF-TBI) in the conditioning regimen. We also extended Treg/Tcon haplo-HSCT to patients that are unfit (because of previous comorbidities) and/or too old to withstand high intensity regimens. In these patients the extra-hematologic toxicity of irradiation was reduced with the use of targeted total marrow and lymph node irradiation (TMLI). 40 patients with high risk acute leukemia (36 AML, 4 ALL) received Treg/Tcon haplo-HSCT. All but 3 patients were transplanted in complete remission. 12 younger patients (median age: 28, range: 20-43) received HF-TBI, while 28 older or unfit patients (59, 40-70) received TMLI in the conditioning regimen. HF-TBI (14.4 Gy) was administered in 12 fractions, 3 times a day for 4 days. TMLI was administered by means of Helical Tomotherapy HI-ART (9 fractions, 2 times a day for 4.5 days). Irradiation was followed by chemotherapy with Thiotepa, Fludarabine, and Cyclophosphamide. 2 × 106/kg freshly isolated CD4+CD25+FOXP3+ Tregs were transferred 4 days before the infusion of 1 × 106/kg Tcons and a mega-dose of CD34+ hematopoietic stem cells. No post-transplant pharmacologic GvHD prophylaxis was given. 38/40 patients engrafted. 12 (31%) developed aGvHD grade ³2 (10 are alive and off-therapy). 6 (16%) died because of transplant related complications (2 because of aGvHD, 2 infections, 1 veno-occlusive disease, 1 intracranial hemorrhage). Strikingly, despite the high risk diseases, no patient relapsed after a median follow up of 13 months (range 1-36, Fig. A). Further, only 1 patient developed cGvHD. Thus, cGvHD/Leukemia-free survival was 82% (Fig. B). Treg adoptive transfer allows for the safe infusion of an otherwise lethal dose of donor alloreactive Tcons in the absence of any other form of immune suppression. Our results demonstrate that the potent graft versus leukemia effect of Treg/Tcon adoptive transfer was boosted by high dose marrow irradiation. Thus, this study proves that the right combination of haploidentical Treg/Tcon immunotherapy plus a powerful conditioning regimen can fully eradicate leukemia.
- Published
- 2019
6. The Molecular Spectrum of β- and α-Thalassemia Mutations in Non-Endemic Umbria, Central Italy
- Author
-
Antonella Roetto, Francesco Arcioni, Olivia Minelli, Laura Ceccuzzi, Antonietta Palmieri, Maurizio Caniglia, Cristina Mecucci, Mauro Marchesi, Ylenia Barbanera, Marina Onorato, Paolo Gorello, Antonella Angius, Cecilia Adami, and Antonio Piga
- Subjects
Male ,Thalassemia ,Population ,Clinical Biochemistry ,hemoglobin (Hb) variants ,Hemoglobinopathies ,Italy ,sickle cell disease ,thalassemias ,Emigrants and Immigrants ,Ethnic Groups ,Female ,Humans ,Mutation ,alpha-Thalassemia ,beta-Thalassemia ,Hematology ,Genetics (clinical) ,Biochemistry (medical) ,Alpha-thalassemia ,Gene mutation ,Biology ,Compound heterozygosity ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Ethnicity ,education ,Genetics ,education.field_of_study ,Beta thalassemia ,medicine.disease ,030220 oncology & carcinogenesis ,Cohort ,030215 immunology - Abstract
The aim of this study was to describe the mutational spectrum of hemoglobinopathies during the period 1988-2015 in Umbria, Central Italy, which has never been considered endemic for these conditions. Twenty-four different β-globin gene mutations were identified in 188 patients and eight different α-globin gene mutations in 74 patients. Sixty percent β-thalassemia (β-thal), 85.0% sickle cell disease, 44.0% Hb S (HBB: c.20A>T)/β-thal and 85.0% compound heterozygotes for hemoglobin (Hb) variant-carrying patients were diagnosed or molecularly characterized in the last 3 years. Moreover, most homozygous or compound heterozygous patients (84.5%) came from foreign countries, while only 15.5% were of Italian origin. These data are in accordance with the increasing foreign resident population in Umbria, which has nearly doubled in 10 years (2004-2014). Different from β-globin gene variations, no increasing trend in α defects was observed in our study cohort. Consistently, 58.0% of patients have an Italian origin, suggesting no broad influence of foreign migration in the α-globin genes genetic background. As few defects are prevalent in each country of origin or ethnic group, their knowledge may provide a proper strategy for the identification of mutations in immigrant individuals in a non-endemic region and be important for carrier identification and prenatal screening.
- Published
- 2017
7. Graft engineering for allogeneic haploidentical stem cell transplantation
- Author
-
Stelvio Ballanti, Franco Aversa, Feliciana Battelli, Roberta Iacucci Ostini, Mauro Di Ianni, Olivia Minelli, Katia Fettucciari, Antonella Santucci, Michele Cimminiello, Antonio Tabilio, Monia Capponi, Tiziana Zei, Massimo F. Martelli, Emanuela Rosati, Carla Silvani, Elisabetta Bonifacio, Maria De Ioanni, Franca Falzetti, and Pierfrancesco Marconi
- Subjects
medicine.medical_treatment ,Transplants ,Lymphoproliferative disorders ,Cell Separation ,Human leukocyte antigen ,Hematopoietic stem cell transplantation ,Lymphocyte Depletion ,Hematopoietic Stem Cell Transplantation ,Humans ,Graft Engineering ,haploidentical Transplantation ,medicine ,Molecular Biology ,Tissue Engineering ,business.industry ,Hematopoietic stem cell ,Cell Biology ,Hematology ,medicine.disease ,Histocompatibility ,Transplantation ,Haematopoiesis ,surgical procedures, operative ,medicine.anatomical_structure ,Immunology ,Molecular Medicine ,Stem cell ,business - Abstract
Haploidentical stem cell transplantation has became a clinical reality in the last 10 years as it provides the chance of transplant for about 50% of patients with hematological malignancies who do not have a matched related or unrelated donor. Proper graft preparation for this type of transplant is crucial and this paper analyses our work over the past decade in the search for the optimal graft processing procedure moving from E-rosetting and soybean agglutination, through a combination of negative or positive selection of hematopoietic stem cells to the current method of one-step positive selection. In preparing a graft for haploidentical transplant, three essential requisites must be met. It must contain (1) a megadose (>10 x 10(6) x kg recipient b.w.) of hematopoietic stem cells to overcome the HLA histocompatibility barrier; (2) very few T-lymphocytes (CD3+ cells < 3 x 10(4)/kg recipient b.w.) to prevent severe acute and chronic graft-versus-host disease (GvHD); (3) very few B-lymphocytes to prevent Epstein-Barr virus-related lymphoproliferative disorders. With current graft processing technologies based on positive selection of hematopoietic stem cells, these requirements can be met. A 70-80% hematopoietic stem cell recovery ensures the target megadose is achieved in over 70% of cases with a T-cell depletion of more than 4 logs and a B-cell depletion of over 3 logs. Progress in graft processing has ensured primary, sustained engraftment rates of over 90% and has significantly reduced the incidence of severe acute GvHD and EBV-related lymphoproliferative disorders. Modern time-saving automated graft processing devices ensure reproducibility, reliability, and biological safety, which make widespread application of the haploidentical transplant currently feasible.
- Published
- 2004
8. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin’s lymphoma
- Author
-
Antonia Reale, Stelvio Ballanti, Massimo F. Martelli, Roberto Ria, Angelo Vacca, Olivia Minelli, Mauro Di Ianni, Franco Dammacco, Franca Falzetti, Gabriella Serio, and G Iodice
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Transplantation Conditioning ,Dacarbazine ,Kaplan-Meier Estimate ,ThioTEPA ,Vinblastine ,Transplantation, Autologous ,Disease-Free Survival ,Carboplatin ,Bleomycin ,Young Adult ,chemistry.chemical_compound ,Autologous stem-cell transplantation ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Etoposide ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Hodgkin's lymphoma ,medicine.disease ,Hodgkin Disease ,Chemotherapy regimen ,Survival Rate ,Transplantation ,Treatment Outcome ,chemistry ,Doxorubicin ,Immunology ,business ,Thiotepa ,medicine.drug - Abstract
Background: Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin’s lymphoma (HL). We studied a high-dose chemotherapy regimen based on thiotepa, etoposide and carboplatin (TECA).Methods: Fifty-eight patients with advanced HL were treated with thiotepa, etoposide and carboplatin for transplant induction.Results: The overall response rate was 79·3% (39 CR: 67·2%; and 7 PR: 12·1%); 12 patients (20·1%) were non-responders. The 5-year overall survival rate was 77·6%; five initially responder patients relapsed within the first 5 years of follow-up and underwent salvage therapy.Conclusion: The TECA conditioning regimen for ASCT in HL results in a good anti-HL effect, positive response to treatment and high 5-year overall survival rate. It was also well tolerated and did not induce excessive toxicity, suggesting that TECA may be a very useful conditioning regimen for HL.
- Published
- 2012
9. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma
- Author
-
Massimo F. Martelli, Angelo Vacca, Olivia Minelli, Antonio Tabilio, Franco Dammacco, Roberto Ria, Michele Cimminiello, Mauro Di Ianni, Franca Falzetti, and Stelvio Ballanti
- Subjects
Melphalan ,Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Cyclophosphamide ,medicine.medical_treatment ,Urology ,Transplantation, Autologous ,Autologous stem-cell transplantation ,Maintenance therapy ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,Antineoplastic Agents, Alkylating ,Busulfan ,Multiple myeloma ,Chemotherapy ,business.industry ,Graft Survival ,Hematology ,Middle Aged ,medicine.disease ,Survival Analysis ,Transplantation ,Regimen ,surgical procedures, operative ,Female ,business ,Multiple Myeloma ,medicine.drug ,Stem Cell Transplantation - Abstract
INTRODUCTION High-dose chemotherapy conditioning regimens for autologous stem cell transplantation generally give similar results in multiple myeloma. We compared two regimens: melphalan versus melphalan plus busulphan. METHODS In all, 30 untreated patients with stage III low-risk multiple myeloma were studied. After induction with three VAD courses and mobilization with cyclophosphamide 7 g/m(2) and recombinant human granulocyte-colony stimulating factor (rHuG-CSF) (10 microg/kg b.w./die), they received melphalan 200 mg/m(2) (arm A) or busulphan 16 mg/kg plus melphalan 100 mg/m(2) (arm B) for conditioning for transplantation. All patients received maintenance therapy with Interferon 3 MU x 3/week. RESULTS Time to engraftment after transplantation was similar in both groups. All patients received rHuG-CSF after reinfusion of peripheral stem cells. No differences emerged in transplant-related infective and noninfective complications. There were no transplant-related deaths. A better response was observed in the melphalan plus busulphan regimen (85 versus 75%, P
- Published
- 2004
10. G-CSF-induced thrombocytopenia in a healthy donor
- Author
-
C Silvani, S Plebani, Olivia Minelli, Antonio Tabilio, Franca Falzetti, M Di Ianni, and M Onorato
- Subjects
Transplantation ,Text mining ,business.industry ,Immunology ,Medicine ,Hematology ,Healthy donor ,business - Published
- 2008
11. Selection of a panel of monoclonal antibodies for monitoring residual disease in peripheral blood and bone marrow of interferon-treated hairy cell leukaemia patients
- Author
-
Brunangelo Falini, Stefano Pileri, Roberto Gerli, Poggi S, L. Flenghi, Olivia Minelli, M. F. Martelli, Marina Liberati, H Stein, and Lauria F
- Subjects
Pathology ,medicine.medical_specialty ,medicine.drug_class ,CD11c ,Monoclonal antibody ,Immunoenzyme Techniques ,Antigen ,Antigens, Neoplasm ,Bone Marrow ,medicine ,Biomarkers, Tumor ,Humans ,Hairy cell leukemia ,CD20 ,Leukemia, Hairy Cell ,alpha interferon ,alphan1 interferon ,beta interferon ,monoclonal antibody ,biology ,business.industry ,Antibodies, Monoclonal ,Hematology ,medicine.disease ,medicine.anatomical_structure ,biology.protein ,Alkaline phosphatase ,Hairy Cell ,Bone marrow ,Interferons ,business - Abstract
Summary A panel of monoclonal antibodies (mAbs) directed against B-cell and hairy cell leukaemia (HCL)-associated antigens was used to identify residual hairy cells in the peripheral blood and/or bone marrow samples from 20 patients with HCL. following treatment with interferon-alpha (IFN-alpha) or interferon-beta (IFN-beta). In all cases, hairy cells retained their characteristic phenotype, e.g. positivity for CD22, CD11c, CD25, CD32, and the HCL-associated trimeric protein (t-GP) recognized by the mAbs HML-1, B-ly7, LF61 and Ber-Act8. The most specific marker for identifying a small percentage of hairy cells in peripheral blood cytospins. was t-GP. In alkaline phosphatase/anti alkaline phosphatase (APAAP) stained preparations, t-GP+ hairy cells (provided with large cytoplasm and hairy surface) could be usually distinguished from t-GP+ normal lymphocytes (small-sized cells with smooth surface). In doubtful cases the percentage of residual hairy cells could exactly be estimated by double immunofluorescence staining for CD22 (B-cell marker) and t-GP. The rationale of the test is based on the finding that the small percentage (about 1%) of t-GP + lymphocytes circulating in the peripheral blood of normal individuals are T-cells of the CD8 subset and not B-cells. The best markers for identifying residual hairy cells in routine bone marrow biopsies were CD45RA (mAb 4KB5) and CD20 (mAb L26). Immunohistological labelling was superior to morphological examination in picking up scattered hairy cells in bone marrow biopsies showing either severe hypoplasia or exuberant hyperplasia of normal haemopoietic series.
- Published
- 1990
12. Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies
- Author
-
L. Flenghi, M F Martelli, Johannes Gerdes, S. Canino, Brunangelo Falini, Olivia Minelli, Marta Fagioli, Stefano Pileri, Stefano Sacchi, C. Ciani, Harald Stein, and Marco Gobbi
- Subjects
Pathology ,medicine.medical_specialty ,Proliferative index ,Lymphoma ,medicine.drug_class ,Monoclonal antibody ,Antigen ,Bone Marrow ,hemic and lymphatic diseases ,medicine ,Humans ,BrdU ,Multiple myeloma ,business.industry ,Antibodies, Monoclonal ,Hematology ,medicine.disease ,Immunohistochemistry ,Leukemia, Lymphoid ,Leukemia ,medicine.anatomical_structure ,Bromodeoxyuridine ,Ki-67 ,monoclonal antibody ,Bone marrow ,business ,Multiple Myeloma ,Cell Division - Abstract
The monoclonal antibody Ki-67, directed against a nuclear antigen expressed by dividing cells in all the phases of cell cycle except G0 and early G1, was used in combination with an anti-BrdU monoclonal antibody, reacting selectively with cells in S-phase, for assessing the percentage of proliferating cells in bone marrow and peripheral blood samples from patients with lymphoma, leukaemia and multiple myeloma. Immunocytochemical labelling of proliferating cells was performed on marrow frozen sections and/or cytospins using an immunoalkaline phosphatase (APAAP) technique that made it possible to obtain proliferative index measurements in a few hours in contrast to the 3–7 d needed with tritiated thymidine. In the 54 marrow lymphoma cases studied a highly significant correlation was observed between the proportion of Ki-67 (+) cells and the separation into low- and high-grade malignant lymphomas according to the Kiel classification. In patients with multiple myeloma at the first diagnosis, the percentage of Ki-67 (+) cells was low (6–10%). In contrast, a high percentage of Ki-67 (+) cells (40–50%) was observed in a young adult with multiple myeloma, in a patient who first presented at the clinical observation with an extradural mass and in three patients who developed extramedullary masses several years after the initial diagnosis of myeloma. In acute lymphoblastic leukaemias of common type the mean value of Ki-67 labelling was 31.3%. Because of their simplicity and rapidity, immunocytochemical techniques may be expected to replace autoradiography and flow cytometry for the detection of proliferating cells in haematological samples.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.